Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
453.36
-0.38 (-0.08%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
69
70
Next >
This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
↗
February 12, 2025
Via
Benzinga
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
↗
February 11, 2025
Via
Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
↗
February 11, 2025
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.
Via
Investor's Business Daily
Vertex: Strong Sales, Stronger Pipeline
↗
February 11, 2025
Via
The Motley Fool
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
February 11, 2025
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Via
StockStory
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
↗
February 11, 2025
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller.
Via
Stocktwits
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
↗
February 04, 2025
Via
Benzinga
Vertex Pharmaceuticals Unusual Options Activity
↗
February 03, 2025
Via
Benzinga
Markets Steady, Positive; Q4 Earnings Keep Rolling
↗
February 10, 2025
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline...
Via
Talk Markets
Topics
Government
Stocks / Equities
World Trade
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
↗
February 10, 2025
VRTX earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Vertex's Revenue Surges but EPS Slips
↗
February 10, 2025
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Via
The Motley Fool
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
February 10, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the...
Via
StockStory
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
↗
February 10, 2025
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth potential. Stock has bullish technicals but risks remain.
Via
Benzinga
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
↗
February 10, 2025
Via
Benzinga
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst
↗
February 10, 2025
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.
Via
Benzinga
Topics
World Trade
Earnings Scheduled For February 10, 2025
↗
February 10, 2025
Via
Benzinga
McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday
↗
February 10, 2025
Stock futures up, focus on McDonald's, ON Semiconductor, VOXX, Rockwell Automation, Vertex Pharmaceuticals.
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in February
↗
February 09, 2025
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
February 09, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Via
StockStory
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades'
↗
February 06, 2025
UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.
Via
Benzinga
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
↗
February 04, 2025
Via
The Motley Fool
3 Magnificent Stocks to Buy and Hold Forever
↗
February 03, 2025
Via
The Motley Fool
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
↗
February 02, 2025
Via
The Motley Fool
What You Missed On Friday
↗
February 02, 2025
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Topics
Stocks / Equities
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
↗
February 02, 2025
Via
The Motley Fool
Small- To Mid-Cap Biotech Trades Poised For Gains
↗
February 01, 2025
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
↗
January 31, 2025
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.
Via
Benzinga
Topics
Cannabis
What's going on in today's session: S&P500 movers
↗
January 31, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via
Chartmill
Top S&P500 movers in Friday's session
↗
January 31, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
69
70
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today